公开(公告)号：EP1651653B1

公开(公告)日：2011-11-23

申请号：EP04740985.9

申请日：2004-07-14

申请人： Sanofi-Aventis Deutschland GmbH

发明人： WAGNER, Holger ,  SCHOENAFINGER, Karl ,  JAEHNE, Gerhard ,  GAUL, Holger ,  BUNING, Christian ,  TSCHANK, Georg ,  WERNER, Ulrich

IPC分类号： C07D513/04 ,  A61K31/415

CPC分类号： C07D487/04

摘要： The invention relates to compounds of formula (I), wherein the radicals have the meanings indicated in the text, the stereoisomeric forms thereof, the physiologically acceptable salts thereof, and methods for the production thereof. The inventive compounds are suitable for the treatment of metabolic diseases such as type 2 diabetes.

公开(公告)号：EP2114937A1

公开(公告)日：2009-11-11

申请号：EP08706994.4

申请日：2008-01-11

申请人： Sanofi-Aventis

发明人： KEIL, Stefanie ,  DEFOSSA, Elisabeth ,  SCHOENAFINGER, Karl ,  SCHMOLL, Dieter ,  DIETRICH, Axel ,  KUHLMANN, Johanna ,  ENGEL, Karl-Christian

IPC分类号： C07D417/14 ,  A61K31/5415 ,  A61P3/10 ,  C07D417/12 ,  C07D513/04

CPC分类号： C07D417/12 ,  C07D417/14 ,  C07D513/04

摘要： The invention relates to compounds of the formula (I), wherein the radicals R1, R2, R3, R4, R5, R6 and R7 and A and B are defined as indicated, and also to the physiologically tolerable salts thereof. The compounds are suited, for example, as anti-diabetics.

公开(公告)号：EP1523471B1

公开(公告)日：2009-09-16

申请号：EP03740386.2

申请日：2003-06-30

申请人： Sanofi-Aventis Deutschland GmbH

发明人： DEFOSSA, Elisabeth ,  KADEREIT, Dieter ,  KLABUNDE, Thomas ,  BURGER, Hans-Joerg ,  HERLING, Andreas ,  WENDT, Karl-Ulrich ,  VON ROEDERN, Erich ,  SCHOENAFINGER, Karl

IPC分类号： C07C275/54 ,  C07D239/96 ,  A61K31/17 ,  A61P3/10

CPC分类号： C07D295/135 ,  C07C275/54 ,  C07D239/96

摘要： The invention relates to urea-substituted and urethane-substituted acylureas, to physiologically compatible salts thereof and to their physiologically functional derivatives. The invention thus relates to compounds of formula (I), wherein the radicals have the cited meanings. The invention also relates to the physiologically compatible salts of these compounds and to methods for the production thereof. The inventive compounds are suited for use, for example, as antidiabetics.

公开(公告)号：EP1937658A1

公开(公告)日：2008-07-02

申请号：EP06805856.9

申请日：2006-09-26

申请人： Sanofi-Aventis

发明人： KEIL, Stefanie ,  SCHOENAFINGER, Karl ,  MATTER, Hans ,  URMANN, Matthias ,  GLIEN, Maike ,  WENDLER, Wolfgang ,  SCHAEFER, Hans-Ludwig ,  FALK, Eugen

IPC分类号： C07D285/12 ,  C07D417/12 ,  A61K31/433 ,  A61P3/10 ,  A61P25/28

CPC分类号： C07D285/135 ,  C07D417/12

摘要： The invention relates to 4-oxy-N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARalpha, PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

摘要翻译： 本发明涉及显示PPARα，PPARδ和PPARγ激动剂活性的4-氧-N- [1,3,4] - 噻二唑-2-基苯磺酰胺及其生理学上可接受的盐和生理学功能衍生物。 所描述的是式（I）化合物，其中基团如所定义，及其生理上可接受的盐和其制备方法。 所述化合物适用于治疗和/或预防脂肪酸代谢和葡萄糖利用障碍的病症，以及涉及中枢和外周神经系统的胰岛素抵抗以及脱髓鞘和其他神经变性病症的病症。

公开(公告)号：EP1863817A1

公开(公告)日：2007-12-12

申请号：EP06723254.6

申请日：2006-03-07

申请人： sanofi-aventis

发明人： DEFOSSA, Elisabeth ,  SCHOENAFINGER, Karl ,  JAEHNE, Gerhard ,  BUNNING, Christian ,  TSCHANK, Georg ,  WERNER, Ulrich

IPC分类号： C07D487/04 ,  A61P3/00 ,  A61P9/00 ,  A61K31/4184

CPC分类号： C07D487/04

摘要： The invention relates to substituted, bicyclic 8-pyrrolidino-benzimidazoles, in addition to the physiologically compatible salts and physiologically functional derivatives of said compounds. The invention relates to compounds of formula (I), in which the groups are defined as cited in the description and to the physiologically compatible salts of said compounds. The compounds are suitable for use, for example, as medicaments for the prevention and treatment of type 2 diabetes.

公开(公告)号：EP1603895A1

公开(公告)日：2005-12-14

申请号：EP04713467.1

申请日：2004-02-21

申请人： Sanofi-Aventis Deutschland GmbH

发明人： SCHOENAFINGER, Karl ,  KADEREIT, Dieter ,  DEFOSSA, Elisabeth ,  HERLING, Andreas ,  KLABUNDE, Thomas

IPC分类号： C07D401/04 ,  A61K31/444

CPC分类号： C07D401/04

摘要： The invention relates to substituted benzoylureidopyridyl-piperidine and -pyrrolidine carboxylic acid derivatives, to a method for the production thereof, and to their use. The invention concerns both compounds of formula (I), wherein the radicals have the cited meanings, as well as physiologically compatible salts of said compounds. These compounds are suited for use as, e.g. medicaments for preventing and treating Type 2 diabetes.

公开(公告)号：EP1753743B1

公开(公告)日：2015-03-04

申请号：EP05745652.7

申请日：2005-05-17

申请人： Sanofi-Aventis Deutschland GmbH

发明人： HOELDER, Swen ,  MUELLER, Guenter ,  SCHOENAFINGER, Karl ,  WILL, David, William ,  MATTER, Hans ,  BOSSART, Martin

IPC分类号： C07D401/14 ,  C07D403/04 ,  A61K31/501 ,  A61K31/5377 ,  A61P3/00 ,  A61P25/00 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  A61K31/553 ,  A61K31/55

CPC分类号： C07D401/14 ,  C07D403/04 ,  C07D471/04

公开(公告)号：EP1651649B1

公开(公告)日：2010-12-01

申请号：EP04740981.8

申请日：2004-07-14

申请人： Sanofi-Aventis Deutschland GmbH

发明人： SCHOENAFINGER, Karl ,  WAGNER, Holger ,  JAEHNE, Gerhard ,  GAUL, Holger ,  BUNING, Christian ,  TSCHANK, Georg ,  WERNER, Ulrich

IPC分类号： C07D487/04 ,  A61K31/415

CPC分类号： C07D487/04

摘要： The invention relates to compounds of formula (I) wherein the radicals have the designations cited in the text. The invention also relates to the stereoisomer forms and the physiologically compatible salts thereof, the physiologically functional derivatives thereof, and methods for producing the same. The inventive compounds are suitable for treating illnesses of the metabolism such as type 2 diabetes.

公开(公告)号：EP2102198A1

公开(公告)日：2009-09-23

申请号：EP07846915.2

申请日：2007-11-30

申请人： Sanofi-Aventis

发明人： KEIL, Stefanie ,  URMANN, Matthias ,  SCHOENAFINGER, Karl ,  WENDLER, Wolfgang ,  GLIEN, Maike ,  SCHAEFER, Hans-Ludwig ,  FALK, Eugen

IPC分类号： C07D413/12 ,  A61K31/4245 ,  A61K31/4725 ,  A61P3/06

CPC分类号： C07D413/12

摘要： The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

公开(公告)号：EP1937659A1

公开(公告)日：2008-07-02

申请号：EP06805858.5

申请日：2006-09-26

申请人： Sanofi-Aventis

发明人： SCHOENAFINGER, Karl ,  KEIL, Stefanie ,  URMANN, Matthias ,  MATTER, Hans ,  GLIEN, Maike ,  WENDLER, Wolfgang

IPC分类号： C07D285/12 ,  A61K31/433 ,  A61P3/10 ,  A61P25/28

CPC分类号： C07D417/12 ,  C07D285/135

摘要： The invention relates to cyclic N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.